about
Structural analysis and tissue localization of human C4.4A: a protein homologue of the urokinase receptorCrystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptideSolution structure of recombinant somatomedin B domain from vitronectin produced inPichia pastorisStabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformationHeterogeneity in the properties of mutant secreted lymphocyte antigen 6/urokinase receptor-related protein 1 (SLURP1) in Mal de MeledaStructure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptorNeutralisation of uPA with a monoclonal antibody reduces plasmin formation and delays skin wound healing in tPA-deficient miceCarbohydrate as covalent crosslink in human inter-alpha-trypsin inhibitor: a novel plasma protein structure.Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallographySelective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammationIdentification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a cCharacterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites.One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry.Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region.Hydrogen atom scrambling in selectively labeled anionic peptides upon collisional activation by MALDI tandem time-of-flight mass spectrometry.Multimerization of glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 (GPIHBP1) and familial chylomicronemia from a serine-to-cysteine substitution in GPIHBP1 Ly6 domainAdministration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in miceTargeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice.Improved PET imaging of uPAR expression using new (64)Cu-labeled cross-bridged peptide ligands: comparative in vitro and in vivo studies.Protein-binding RNA aptamers affect molecular interactions distantly from their binding sitesConformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction.Plasmodium ookinetes coopt mammalian plasminogen to invade the mosquito midgut.Expression of C4.4A, a structural uPAR homolog, reflects squamous epithelial differentiation in the adult mouse and during embryogenesisMimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor.The urokinase receptor as a potential target in cancer therapy.Peptide-Based Optical uPAR Imaging for Surgery: In Vivo Testing of ICG-Glu-Glu-AE105First-in-human uPAR PET: Imaging of Cancer Aggressiveness.Urokinase-type plasminogen activator-like proteases in teleosts lack genuine receptor-binding epidermal growth factor-like domains.A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR)The acidic domain of the endothelial membrane protein GPIHBP1 stabilizes lipoprotein lipase activity by preventing unfolding of its catalytic domain.C4.4A gene ablation is compatible with normal epidermal development and causes modest overt phenotypes.The urokinase receptor homolog Haldisin is a novel differentiation marker of stratum granulosum in squamous epithelia.The urokinase receptor and regulation of cell surface plasminogen activation.Tousled-like kinases phosphorylate Asf1 to promote histone supply during DNA replication.Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes.Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist.Expression and crystallographic studies of the D1D2 domains of C4.4A, a homologous protein to the urokinase receptor.Monoclonal antibodies that bind to the Ly6 domain of GPIHBP1 abolish the binding of LPL.Mobility of "HSPG-bound" LPL explains how LPL is able to reach GPIHBP1 on capillaries.
P50
Q24315974-33140301-0315-4FA3-99B5-D1D97C461EB5Q24529128-276C38EA-4169-45F8-8C7B-38B97DE1010EQ27647777-58595BCE-74EC-462A-93A9-8BCD71D72BC8Q27697915-AC1A7016-12ED-44FD-B6C2-EB484B04A100Q28119056-6E1DC832-E529-43FB-A2C0-6885B0F5536DQ28188116-C8C46845-3B10-4722-A887-0DF36151A18CQ28749280-2DB69372-52B2-40C8-8133-34ACE7903EB6Q30358808-BCB886BF-42E2-49DC-8FB2-91E66B9D63AAQ30380709-0AFC42CB-FC7A-4286-9628-467A7E4AABC0Q30496585-A7BD277E-C7D8-4A26-8D00-569052941D12Q31960282-B450C347-2F29-4EAD-835C-7B850418DE12Q33198870-2FCCCC4D-87DB-45D0-86FC-ECD3407C1A88Q33259686-184458AB-5433-43EE-91E4-0F7D07E1BAF5Q33278178-1E6B5476-4458-41C8-A704-D553465B5791Q33353182-22F16B75-AB37-4683-AAE0-AB3E00F033D7Q33888534-23278F99-596E-4077-A8B9-126C4007E813Q33974535-B8557DE9-C755-4A84-B802-AAA7D5BCB06AQ34434875-F89708C1-A361-4B2F-B073-F5B7CAF03FB2Q34766934-FF58E589-B089-4AB2-9038-5E42153D4678Q34992753-9BC1A10A-3CF0-4FD9-9F88-37A101AAAFBCQ35203415-D485BC90-4636-4554-97ED-20727B7CEDB5Q35312973-DEFE5EA9-7ABA-4C4A-8499-55C505A1BFD3Q35346248-D5BF12B1-9BD4-4D58-8DBE-D6D6871FE0A7Q35440794-85B16906-AA21-446B-AA3D-809C1322EA4BQ35604600-0E18663D-406E-4BC6-994A-56F999647D3DQ35848290-47739121-44CB-4984-ABDD-75BDBD5C17BFQ35909379-67B281E0-444C-4C2E-B1E3-32D1867BA730Q36191589-AA40B1C8-895B-4100-B60F-C14E05FE5EBDQ36201781-FF6D892F-E0C2-41B2-8E66-ABC3057E1465Q36298409-3C7CC932-DC99-4830-98EB-24C32CC83D2AQ36585939-53106AFC-186C-43E7-B3C0-E375396ED6C4Q36893729-3664B61C-25F9-4691-ADB7-5FFFDD704C87Q37255861-C835624B-F0C7-4563-8C1C-004A21A4CFF3Q37573846-BF8308F6-9075-43B4-997D-878841BA65B8Q37687161-30E34618-35D0-430C-BE1A-F378AFDC0C28Q37894756-9D0486C8-D13F-4E47-A931-2F9DB3F40F5CQ38120755-5F7DCC4A-8C55-49E5-B250-4273B614C5DCQ38641204-49C7CA5E-5D5D-465A-94A0-608AC6DFFD6BQ38729657-0768C268-2E64-4E35-91D3-0A6A5F30AC63Q38733084-E3AE0E28-1DB7-4CFD-ACFD-53531D016AE0
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Michael Ploug
@ast
Michael Ploug
@en
Michael Ploug
@es
Michael Ploug
@nl
Michael Ploug
@sl
type
label
Michael Ploug
@ast
Michael Ploug
@en
Michael Ploug
@es
Michael Ploug
@nl
Michael Ploug
@sl
prefLabel
Michael Ploug
@ast
Michael Ploug
@en
Michael Ploug
@es
Michael Ploug
@nl
Michael Ploug
@sl
P214
P106
P1153
7003307551
P21
P214
P31
P496
0000-0003-2215-4265
P734
P735
P7859
viaf-307267987